Robert T. Manguso

Jul 11, 2024 | einpresswire.com | Robert T. Manguso

A number of cancers, including certain brain and liver tumors, as well as myeloid leukemias, are driven by mutations in the enzyme isocitrate dehydrogenase 1, or IDH1. Drugs that block mutated IDH1 (mIDH1) have recently come onto the market and effectively slow tumor growth, but the exact mechanism at work to stall tumors is still unclear. Reporting in , researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard have made a surprising discovery about these drugs.

Jul 11, 2024 | broadinstitute.org | Ari Navetta |Robert T. Manguso

A number of cancers, including certain brain and liver tumors, as well as myeloid leukemias, are driven by mutations in the enzyme isocitrate dehydrogenase 1, or IDH1. Drugs that block mutated IDH1 (mIDH1) have recently come onto the market and effectively slow tumor growth, but the exact mechanism at work to stall tumors is still unclear.

Dec 4, 2023 | nature.com | Keene L. Abbott |Audrey J. Muscato |Kathleen B. Yates |Juan Dubrot |John G. Doench |Marcela V. Maus | +3 more

AbstractCAR-T therapy is a promising, novel treatment modality for B-cell malignancies and yet many patients relapse through a variety of means, including loss of CAR-T cells and antigen escape. To investigate leukemia-intrinsic CAR-T resistance mechanisms, we performed genome-wide CRISPR-Cas9 loss-of-function screens in an immunocompetent murine model of B-cell acute lymphoblastic leukemia (B-ALL) utilizing a modular guide RNA library.